CY1119361T1 - 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις - Google Patents
3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσειςInfo
- Publication number
- CY1119361T1 CY1119361T1 CY20171101039T CY171101039T CY1119361T1 CY 1119361 T1 CY1119361 T1 CY 1119361T1 CY 20171101039 T CY20171101039 T CY 20171101039T CY 171101039 T CY171101039 T CY 171101039T CY 1119361 T1 CY1119361 T1 CY 1119361T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dihydroisoquinoline
- material compounds
- formula
- compounds
- dihydroisoquinollv
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η εφεύρεση παρέχει ορισμένες 3,4-διυδροϊσοκινολlv-2(1Η)-υλικές ενώσεις, ιδιαίτερα ενώσεις με τύπο (I), και φαρμακευτικές συνθέσεις αυτών. Η εφεύρεση παρέχει επιπλέον μεθόδους για τη χρήση μίας ένωσης με τύπο (I)για τη θεραπεία της γνωστικής δυσλειτουργίας που σχετίζεται με τη νόσο του Πάρκινσον ή τη σχιζοφρένεια.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828740P | 2013-05-30 | 2013-05-30 | |
| US201361905329P | 2013-11-18 | 2013-11-18 | |
| PCT/US2014/039494 WO2014193781A1 (en) | 2013-05-30 | 2014-05-27 | 3,4-dihydroisoquinolin-2(1h)-yl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119361T1 true CY1119361T1 (el) | 2018-02-14 |
Family
ID=50983199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101039T CY1119361T1 (el) | 2013-05-30 | 2017-10-05 | 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US8962654B2 (el) |
| EP (1) | EP3004061B8 (el) |
| JP (2) | JP6130590B2 (el) |
| KR (1) | KR101808933B1 (el) |
| CN (1) | CN105228985B (el) |
| AP (1) | AP2015008867A0 (el) |
| AU (2) | AU2014274435B2 (el) |
| BR (1) | BR112015029090B1 (el) |
| CA (1) | CA2912849C (el) |
| CL (1) | CL2015003444A1 (el) |
| CR (1) | CR20150622A (el) |
| CY (1) | CY1119361T1 (el) |
| DK (1) | DK3004061T3 (el) |
| DO (1) | DOP2015000289A (el) |
| EA (1) | EA029220B1 (el) |
| ES (1) | ES2647086T3 (el) |
| GT (1) | GT201500334A (el) |
| HR (1) | HRP20171696T1 (el) |
| HU (1) | HUE034607T2 (el) |
| JO (1) | JO3316B1 (el) |
| LT (1) | LT3004061T (el) |
| ME (1) | ME02838B (el) |
| MX (1) | MX373843B (el) |
| MY (1) | MY180751A (el) |
| NZ (1) | NZ713809A (el) |
| PE (1) | PE20152032A1 (el) |
| PH (1) | PH12015502658B1 (el) |
| PL (1) | PL3004061T3 (el) |
| PT (1) | PT3004061T (el) |
| RS (1) | RS56294B1 (el) |
| SG (1) | SG11201509310QA (el) |
| SI (1) | SI3004061T1 (el) |
| TN (1) | TN2015000514A1 (el) |
| TW (2) | TWI691489B (el) |
| UA (1) | UA118759C2 (el) |
| WO (1) | WO2014193781A1 (el) |
| ZA (1) | ZA201508213B (el) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ625712A (en) | 2009-11-27 | 2016-02-26 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| AR106332A1 (es) * | 2015-10-23 | 2018-01-03 | Lilly Co Eli | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| EP3585387A4 (en) | 2017-02-21 | 2020-08-12 | Emory University | CHEMIOKIN CXCR4 RECEIVER MODULATORS AND THEIR USES |
| EP3418270A1 (en) | 2017-06-19 | 2018-12-26 | Universidad Complutense De Madrid | Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor |
| CN111432847A (zh) | 2017-12-01 | 2020-07-17 | Ucb生物制药有限责任公司 | 显像剂 |
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| TWI831896B (zh) | 2018-12-18 | 2024-02-11 | 美商美國禮來大藥廠 | 用於治療多巴胺性cns病症之ly3154207劑量療法 |
| TWI843678B (zh) * | 2019-06-18 | 2024-05-21 | 美商美國禮來大藥廠 | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 |
| MY210361A (en) | 2019-07-01 | 2025-09-13 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| PH12021552819A1 (en) | 2019-07-01 | 2022-09-28 | UCB Biopharma SRL | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
| MD4200280T2 (ro) | 2020-10-07 | 2024-08-31 | Lilly Co Eli | Derivați de fenil-3,4-dihidroizochinolin-2(1H)-il-etan-1-onă în calitate de modulatori alosterici pozitivi ai receptorului de dopamină D1 |
| CN116507332A (zh) | 2020-12-03 | 2023-07-28 | Ucb生物制药有限责任公司 | 八氢异喹啉基衍生物 |
| JP7777589B2 (ja) * | 2020-12-18 | 2025-11-28 | ユーシービー バイオファルマ エスアールエル | ジヒドロイソキノリニル誘導体 |
| ES3004257T3 (en) * | 2020-12-18 | 2025-03-12 | UCB Biopharma SRL | Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone |
| FI4263517T3 (fi) | 2020-12-18 | 2024-12-09 | UCB Biopharma SRL | Substituoitu tetrahydroisokinoliinijohdannainen d1-positiivisena allosteerisenä modulaattorina |
| KR20230121867A (ko) * | 2020-12-18 | 2023-08-21 | 유씨비 바이오파마 에스알엘 | 무정형 고체 분산체 |
| MX2023010540A (es) | 2021-03-08 | 2023-11-24 | Lilly Co Eli | Uso de mevidaleno y otros moduladores alostéricos positivos d1 en el tratamiento de alucinaciones y psicosis relacionadas con la demencia. |
| AU2022234226B2 (en) * | 2021-03-09 | 2025-08-14 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68910999T2 (de) | 1988-02-19 | 1994-03-24 | Smithkline Beecham Farma | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten. |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| IL137720A0 (en) | 1998-02-18 | 2001-10-31 | Neurosearch As | Compounds and their use as positive ampa receptor modulators |
| JP2004507456A (ja) | 2000-05-11 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | 成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体 |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| RU2009136330A (ru) * | 2007-03-01 | 2011-04-10 | Янссен Фармацевтика Н.В. (Be) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора |
| US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| US9255090B2 (en) | 2011-12-21 | 2016-02-09 | Actelion Pharmaceuticals Ltd. | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
-
2014
- 2014-05-15 JO JOP/2014/0163A patent/JO3316B1/ar active
- 2014-05-16 TW TW108104751A patent/TWI691489B/zh active
- 2014-05-16 TW TW103117402A patent/TWI691488B/zh active
- 2014-05-27 EA EA201592082A patent/EA029220B1/ru not_active IP Right Cessation
- 2014-05-27 AP AP2015008867A patent/AP2015008867A0/xx unknown
- 2014-05-27 UA UAA201511029A patent/UA118759C2/uk unknown
- 2014-05-27 ES ES14732756.3T patent/ES2647086T3/es active Active
- 2014-05-27 PL PL14732756T patent/PL3004061T3/pl unknown
- 2014-05-27 NZ NZ71380914A patent/NZ713809A/en unknown
- 2014-05-27 SG SG11201509310QA patent/SG11201509310QA/en unknown
- 2014-05-27 PT PT147327563T patent/PT3004061T/pt unknown
- 2014-05-27 WO PCT/US2014/039494 patent/WO2014193781A1/en not_active Ceased
- 2014-05-27 BR BR112015029090-6A patent/BR112015029090B1/pt active IP Right Grant
- 2014-05-27 HU HUE14732756A patent/HUE034607T2/en unknown
- 2014-05-27 AU AU2014274435A patent/AU2014274435B2/en active Active
- 2014-05-27 HR HRP20171696TT patent/HRP20171696T1/hr unknown
- 2014-05-27 EP EP14732756.3A patent/EP3004061B8/en active Active
- 2014-05-27 CA CA2912849A patent/CA2912849C/en active Active
- 2014-05-27 SI SI201430377T patent/SI3004061T1/sl unknown
- 2014-05-27 MY MYPI2015704341A patent/MY180751A/en unknown
- 2014-05-27 ME MEP-2017-221A patent/ME02838B/me unknown
- 2014-05-27 KR KR1020157033616A patent/KR101808933B1/ko active Active
- 2014-05-27 MX MX2015016495A patent/MX373843B/es active IP Right Grant
- 2014-05-27 TN TN2015000514A patent/TN2015000514A1/en unknown
- 2014-05-27 CN CN201480031030.7A patent/CN105228985B/zh active Active
- 2014-05-27 RS RS20170896A patent/RS56294B1/sr unknown
- 2014-05-27 US US14/287,239 patent/US8962654B2/en active Active
- 2014-05-27 PE PE2015002534A patent/PE20152032A1/es unknown
- 2014-05-27 JP JP2016516713A patent/JP6130590B2/ja active Active
- 2014-05-27 LT LTEP14732756.3T patent/LT3004061T/lt unknown
- 2014-05-27 DK DK14732756.3T patent/DK3004061T3/en active
-
2015
- 2015-11-06 ZA ZA2015/08213A patent/ZA201508213B/en unknown
- 2015-11-23 CR CR20150622A patent/CR20150622A/es unknown
- 2015-11-24 CL CL2015003444A patent/CL2015003444A1/es unknown
- 2015-11-26 GT GT201500334A patent/GT201500334A/es unknown
- 2015-11-27 PH PH12015502658A patent/PH12015502658B1/en unknown
- 2015-11-27 DO DO2015000289A patent/DOP2015000289A/es unknown
-
2016
- 2016-10-07 AU AU2016238934A patent/AU2016238934B2/en active Active
-
2017
- 2017-04-13 JP JP2017079775A patent/JP6387433B2/ja active Active
- 2017-10-05 CY CY20171101039T patent/CY1119361T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119361T1 (el) | 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις | |
| CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CR20150474A (es) | Inhibidores de bromodominios tetracíclicos | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| CR20160456A (es) | Compuestos de heteroarilo o arilo bibíclicos fusionados | |
| CY1122613T1 (el) | Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139 | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| MX382599B (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina. | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| MX373033B (es) | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| TR201900680T4 (tr) | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| CR20150417A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| TR201901977T4 (tr) | Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales |